Age and CMV are not associated with clinical or immunological response to immune checkpoint blockade

Ageing and cytomegalovirus (CMV) infection drive major alterations to T-cell immunity. Age is also associated with an increased risk of cancers including melanoma, which is treated with T-cell modifying immune checkpoint blockade (ICB). However, the extent to which age, CMV, and treatment-induced immune changes interact to shape clinical outcomes remains poorly understood. We investigated this through flow cytometric evaluation of pre- and early on-treatment blood samples of 79 advanced melanoma patients. Age and CMV infection were associated with significant and largely distinct changes to T cell phenotype pre-treatment but had no impact on clinical outcome. Older patients ([≥]65 years) had fewer CD8+ Tnaive, CD4+ Tcm, TFH, and B cells, and increased CD8+ TemRA, but similar cytokine and inhibitory marker expression. Conversely, CMV drove expansion of CD8+ and CD4+ TemRA cells with enhanced effector function without reducing naive populations. One cycle of PD-1 and CTLA-4 ICB induced immune cell expansion and phenotype changes of greater magnitude and partially distinct from those seen during PD-1 with or without LAG-3 ICB, but these effects were largely independent of age or CMV serostatus. Hence, neither ageing nor CMV were associated with clinical outcome or immunological response to ICB in advanced melanoma patients.